AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
HEALTH: South Africa (MRB Oct 01 2001): Coal-based drug causes controversy.
The state-run Central Energy Fund subsidiary, Enerkom's coal-based drug, oxihumate-K, had a rough ride this month. The Johannesburg-based Mail & Guardian called it "a loony new AIDS drug" - memories of the Virodene debacle are still fresh. A senior British HIV clinician also said it was likely to be worthless.
However, Enerkom has denied that it claimed the drug, already on the market as the nutritional supplement, Oximate, is a cure for AIDS, saying instead that it is intended to boost the immune system, helping the body cope with infections.
With HIV/AIDS still rising exponentially in SA and the region the market for a palliative is bound to be lucrative. R80 million has been spent so far on developing the project, a loan Enerkom obtained from the CEF. R3.4-million of the ...
- New Fragment-based Drug Discovery Platform Announced Between IOTA...
- Press release article from: PR Newswire April 23, 2008 700+ words
...leading companies in the area of fragment-based drug discovery (FBDD) today announced a...using a unique combination of fragment-based drug screening and medicinal chemistry-led...heading IOTA, commented, "Fragment-based drug discovery is a fast, efficient and productive...
- Cellomics Launches Cell-Based Drug Discovery Platform, ArrayScan II, for...
- Press release article from: PR Newswire August 2, 1999 700+ words
...release of their proprietary, cell-based drug discovery platform, ArrayScan(TM...advantage of ArrayScan II over other cell-based drug discovery methods is that ArrayScan provides...in October 1996, is focused on cell-based drug discovery. Cellomics' mission is to...
- Breakthrough In Thermochemical-Based Drug Screening, Reported By The Althexis...
- Press release article from: PR Newswire September 11, 2000 700+ words
...unknown function and, consequently, fast-forward genomics-based drug discovery," said Dr. Manuel A. Navia, Althexis's President...sophisticated, classical medicinal chemistry and structure-based drug design (SBDD) methodologies -- encompassing combinatorial...
- Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE...
- Press release article from: PR Newswire January 13, 2009 700+ words
...Beactica AB, the Swedish fragment-based drug discovery company, today announced a...Beactica's unique approach to fragment-based drug discovery and GE Healthcare's Biacore...instruments and applications for fragment-based drug discovery. The project also aims to...
- CytRx provides update on RNAi-based drug discovery programs - progress made...
- Newspaper article from: BIOTECH Patent News February 1, 2006 700+ words
...evolution as a leader in the field of RNAi-based drug discovery in identifying and developing...following developments in its RNAi-based drug discovery programs: * Extension of its...drug candidates derived from our RNAi-based drug discovery program, which represents...
- Evotec Wins Key Contracts With Solvay Pharmaceuticals: Fragment-Based Drug...
- Press release article from: PR Newswire January 22, 2007 700+ words
...as Solvay's partner for fragment-based drug discovery. Solvay will access Evotec...Evotec has validated their fragment-based drug discovery platform against various protein...collaborating with them on the new fragment-based drug discovery programme. We are confident...
- Triad Biotechnology Chooses MSI's Software for Genomics-based Drug Discovery.
- Press release article from: Business Wire November 4, 1998 700+ words
...Triad Biotechnology Inc., a San Diego-based drug discovery company, has made a significant...its research in structural genomics-based drug discovery. Triad (http://www...Triad's integrated genomics-based drug discovery program will be the first enabling...
- Pennsylvania-Based Drug Firm Cephalon to Buy Cima Labs.
- Newspaper article from: Knight Ridder/Tribune Business News November 4, 2003 700+ words
...of Cima Labs Inc. appears to be over as the Eden Prairie-based drug company has signed a merger agreement that looks like it will...to sell itself to Cephalon Inc., a West Chester, Pa.-based drug company, for $34 per share in cash -- about a third more...
